Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status
07 Agosto 2023 - 5:05PM
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing
and precision medicine, announced enhancements to the GeneSight®
Psychotropic test, a pharmacogenomic test for mental health
medications. The GeneSight report will now include information on
how a patient's smoking status may impact their body's metabolism
of certain medications.
Many factors may influence medication outcomes in addition to
genetics. Smoking is one of those factors as it can increase the
activity of CYP1A2 – a gene involved in the metabolism of several
mental health medications – in patients who have the highly
inducible CYP1A2 variant.
For roughly 91% of patients with the CYP1A2 variant, the
categorization and information provided for certain medications can
be affected by smoking status.1 Smoking on the GeneSight report is
defined as the daily inhalation of burning plant material (such as
cigarettes and marijuana). Vaping and e-cigarettes are not
included.
Approximately a third of the medications on the GeneSight report
have CYP1A2 involvement, which means they have the potential to be
categorized differently based on a patient’s smoking status. These
23 medications include several antidepressants, anxiolytics and
hypnotics, and antipsychotics.
“Taking smoking status into consideration helps ensure the test
provides an even more complete picture of patients’ potential
outcomes with certain medications,” said Holly Johnson, Ph.D.,
director of Medical Affairs, Myriad Genetics. “This update was made
based on a comprehensive analysis of peer-reviewed literature and
our continued commitment to provide clinicians with genetic
insights from the GeneSight test to help inform treatment
decisions.”
According to the Centers for Disease Control and Prevention
(CDC), the prevalence of smoking cigarettes in patients who have
depression or mental health symptoms is higher than the general
population. In fact, the American Lung Association states that
“lifetime smoking rates are higher in patients who are diagnosed
with major depression disorder (59%).” Daily or near daily usage of
marijuana is two times higher in individuals with depression
compared to those without it.2 Nearly 80% of marijuana usage is
through smoking.3
The updated test is available immediately for prescribing
clinicians. For more information, please visit
https://genesight.com/for-clinicians/.
About the GeneSight TestThe GeneSight
Psychotropic test from Myriad Genetics is the category-leading
pharmacogenomic test for 64 medications commonly prescribed for
depression, anxiety, ADHD, and other psychiatric conditions. The
GeneSight test can help inform clinicians about how a patient’s
genes may impact how they metabolize and/or respond to certain
psychiatric medications. Tens of thousands of clinicians have
ordered the GeneSight test for more than two million patients in
order to receive genetic information that is unique to each
patient. The GeneSight test supplements other information
considered by a clinician as part of a comprehensive medical
assessment. Learn more at GeneSight.com.
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including that
the GeneSight test report will now include information on how a
patient's smoking status may impact their body's metabolism of
certain medications. These “forward-looking statements” are
management’s expectations of future events as of the date hereof
and are subject to known and unknown risks and uncertainties that
could cause actual results, conditions, and events to differ
materially and adversely from those anticipated. Such factors
include those risks described in the company’s filings with the
U.S. Securities and Exchange Commission, including the company’s
Annual Report on Form 10-K filed on March 1, 2023, as well as any
updates to those risk factors filed from time to time in the
company’s Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. Myriad is not under any obligation, and it expressly disclaims
any obligation, to update or alter any forward-looking statements,
whether as a result of new information, future events or otherwise
except as required by law.
[1] Frequency is based on internal Myriad Neuroscience data of
over 2.1 million tested patients
[2} Gorfinkel, Lauren R et al. (2020). “Association of
Depression With Past-Month Cannabis Use Among US Adults Aged 20 to
59 Years, 2005 to 2016.” JAMA network open vol. 3,8 e2013802
[3] Dai, H. and K.P. Richter. (2019). "A National Survey of
Marijuana Use Among US Adults with Medical Conditions." JAMA
Network Open, 2(9):e1911936
Media Contact:Glenn Farrell(385)
318-3718PR@myriad.com
Investor Contact:Matt Scalo(801)
584-3532IR@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024